SCLC transdifferentiation can also manifest in anaplastic lymphoma kinase (ALK)-translocated NSCLC following ALK-TKI therapy [17], immune-checkpoint inhibitor treatment [18], and even spontaneously without intervention [19]. This evidence concerns the gene ALK and small cell lung carcinoma.